Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (2924)	11/21/1997 11:14:00 AM
From: margie	Read Replies (2) \| Respond to of 6136

Links to several Clinical Trials Including Viracept INDEPENDENT CLINICAL TRIALS GROUP - ICTG sfghaids.ucsf.edu Led by James Kahn, MD, the Independent Clinical Trials Group is organized to conduct cutting-edge research in partnership with pharmaceutical companies and other non-governmental research sponsors. This collaboration offers SFGH investigators the opportunity to have direct input into the design and conduct of early studies of promising new therapies for HIV. The ICTG is an exciting and rapidly growing component of the AIDS Program's research arsenal. Open ICTG Studies: HIV Infection in Newly Seroconverted: VIRACEPT, AZT, 3TC hivinsite.ucsf.edu HIV Infection in Newly Seroconverted: d4T, ddI, Nelfinavir, Hydroxyurea hivinsite.ucsf.edu HIV Infection: Nelfinavir, Hydroxyurea, d4T, ddI hivinsite.ucsf.edu MEETINGS: Adult AIDS Clinical Trials Group Meeting Dates: December 6-10, 1997 (Saturday - Wednesday): Winter ACTG Meeting, Crystal Gateway Marriot, Virginia (Washington DC Area) Practical Management of HIV Disease: Today's Reality, Tomorrow's Hope DATE: Saturday, November 22, 1997 Designed for healthcare providers who manage the care of HIV/AIDS patients, this course's purpose is to discuss the importance of reducing viral load to the lowest possible levels, to outline various treatment options for decreasing viral load, and to review the clinical significance of genotypic and phenotypic resistance to antiretroviral agents. SPEAKERS: John A. Bartlett, MD Duke University Medical Center James Kahn, MD University of California, San Francisco Daniel R. Kuritzkes, MD University of Colorado Health Sciences LOCATION: The Fairmont Hotel 950 Mason Street San Francisco, TELEPHONE: (415)772-5000 REGISTRATION INFORMATION: (800)433-4584 or (within New York State) (800)521-1177 call between 8:30 a.m. & 5:30 p.m. EST. E-MAIL: whcme@whci.41mad.com RESEARCH GROUPS: sfghaids.ucsf.edu CLINICAL TRIALS GROUPS * AIDS Clinical Trials Group (ACTG): Mark Jacobson, MD sfghaids.ucsf.edu * Community Consortium: Donald Abrams, MD * INDEPENDENT CLINICAL TRIALS GROUP (ICTG James Kahn, MD sfghaids.ucsf.edu LABORATORY RESEARCH GROUPS oClinical Virology Laboratory and HIV Viral Pathogenesis Core Lab: Silvija Staprans, PhD and Tarek Elbeik, PhD oHerpes Research Laboratory: Sharon Safrin, MD oAIDS Immunobiology Research Laboratory: Michael McGrath, MD, PhD